|
US8143283B1
(en)
*
|
1993-03-01 |
2012-03-27 |
The Children's Medical Center Corporation |
Methods for treating blood-born tumors with thalidomide
|
|
US6228879B1
(en)
|
1997-10-16 |
2001-05-08 |
The Children's Medical Center |
Methods and compositions for inhibition of angiogenesis
|
|
US6518281B2
(en)
|
1995-08-29 |
2003-02-11 |
Celgene Corporation |
Immunotherapeutic agents
|
|
US5635517B1
(en)
*
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
|
HU228769B1
(en)
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
|
NZ336035A
(en)
*
|
1996-11-05 |
2002-03-28 |
Childrens Medical Center |
Angiogenesis inhibitory composition comprising an inhibitory compound and antiinflammatory drug
|
|
DE69929440T2
(de)
*
|
1998-07-09 |
2006-08-17 |
Cephalon, Inc. |
Zusammensetzungen zur behandlung chronischer lymphatischer leukämie
|
|
AU2023500A
(en)
*
|
1998-11-12 |
2000-05-29 |
Cell Pathways, Inc. |
Method for treating a patient with neoplasia by treatment with an anthracycline antibiotic
|
|
US6235776B1
(en)
*
|
1998-11-12 |
2001-05-22 |
Cell Pathways, Inc. |
Method for treating a patient with neoplasia by treatment with a paclitaxel derivative
|
|
US6235782B1
(en)
*
|
1998-11-12 |
2001-05-22 |
Rifat Pamukcu |
Method for treating a patient with neoplasia by treatment with a platinum coordination complex
|
|
US20030013739A1
(en)
*
|
1998-12-23 |
2003-01-16 |
Pharmacia Corporation |
Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
|
|
KR100672892B1
(ko)
|
1999-03-18 |
2007-01-23 |
셀진 코오퍼레이션 |
치환된 1-옥소- 및 1,3-디옥소이소인돌린스 및 염증성사이토킨 수치를 감소시키기 위한 약학적 조성물로서의이들의 사용
|
|
MXPA01011344A
(es)
*
|
1999-05-07 |
2004-06-03 |
Univ Johns Hopkins Med |
El uso de un inhibidor de la ruta de proteina tirosina quinasa en el tratamiento de trastornos oculares.
|
|
US7629360B2
(en)
*
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
|
MY164077A
(en)
*
|
1999-05-13 |
2017-11-30 |
Pharma Mar Sa |
Compositions and uses of et743 for treating cancer
|
|
WO2000072836A2
(en)
*
|
1999-05-27 |
2000-12-07 |
The Rockefeller University |
Methods of promoting or enhancing interleukin-12 production through administration of thalidomide
|
|
US7105560B1
(en)
*
|
1999-07-23 |
2006-09-12 |
The Regents Of The University Of California |
Use of etodolac in the treatment of multiple myeloma
|
|
US7105172B1
(en)
*
|
1999-11-18 |
2006-09-12 |
Bolla John D |
Treatment of rosacea
|
|
EP1279406A4
(en)
*
|
2000-04-03 |
2007-10-24 |
Santen Pharmaceutical Co Ltd |
TRANSPORTERS AND DRUG DISPENSING SYSTEMS USING THESE
|
|
AU2001261409A1
(en)
*
|
2000-05-11 |
2001-11-20 |
Oklahoma Medical Research Foundation |
Prevention of insulin-dependent diabetes, complications thereof, or allograft rejection by inhibition of cyclooxygenase-2 activity with NS398 or PDTC
|
|
CA2416152A1
(en)
*
|
2000-07-27 |
2002-02-07 |
Pharmacia Corporation |
Aldosterone blocker therapy to prevent or treat inflammation-related disorders
|
|
US6458810B1
(en)
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
|
AU2002253795B2
(en)
*
|
2000-11-30 |
2007-02-01 |
The Children's Medical Center Corporation |
Synthesis of 4-Amino-Thalidomide enantiomers
|
|
AU2002306596B2
(en)
|
2001-02-27 |
2008-01-17 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Analogs of thalidomide as potential angiogenesis inhibitors
|
|
IL142037A0
(en)
|
2001-03-15 |
2002-03-10 |
Agis Ind 1983 Ltd |
Pharmaceutical compositions containing a non-steroidal anti-inflammatory drug
|
|
US6344479B1
(en)
*
|
2001-03-20 |
2002-02-05 |
Farmacon-Il, Llc |
Method of preventing retinopathy of prematurity in a neonate
|
|
CN100353947C
(zh)
*
|
2001-03-28 |
2007-12-12 |
参天制药株式会社 |
以甾体为有效成分的视网膜和脉络膜疾病治疗剂
|
|
WO2003014315A2
(en)
*
|
2001-08-06 |
2003-02-20 |
The Children's Medical Center Corporation |
Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
|
|
CN1318093C
(zh)
*
|
2001-09-28 |
2007-05-30 |
参天制药株式会社 |
含与聚乙二醇结合的药物的眼组织注射剂
|
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
CN102342938B
(zh)
*
|
2002-05-17 |
2014-08-20 |
细胞基因公司 |
用于治疗和控制实体瘤的方法及组合物
|
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
|
EP1556033A4
(en)
*
|
2002-05-17 |
2006-05-31 |
Celgene Corp |
METHODS AND COMPOSITIONS USING CYTOKINE INHIBITOR SELECTIVE MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES
|
|
US7323479B2
(en)
*
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
|
JP2006510606A
(ja)
*
|
2002-10-15 |
2006-03-30 |
セルジーン・コーポレーション |
骨髄異形成症候群を治療および管理するための選択的サイトカイン阻害剤の使用方法およびそれを含む組成物
|
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
|
US20050203142A1
(en)
*
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
|
US20040091455A1
(en)
*
|
2002-10-31 |
2004-05-13 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
|
|
AU2003287381B2
(en)
*
|
2002-10-31 |
2008-03-06 |
Celgene Corporation |
Composition for the treatment of macular degenration
|
|
US8034831B2
(en)
|
2002-11-06 |
2011-10-11 |
Celgene Corporation |
Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies
|
|
EP1567154A4
(en)
|
2002-11-06 |
2006-05-31 |
Celgene Corp |
METHODS AND COMPOSITIONS USING CYTOKINE SELECTIVE INHIBITION DRUGS FOR TREATING AND CONTROLLING CANCERS AND OTHER DISEASES
|
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
|
US9006267B2
(en)
*
|
2002-11-14 |
2015-04-14 |
Celgene Corporation |
Pharmaceutical compositions and dosage forms of thalidomide
|
|
US7230012B2
(en)
*
|
2002-11-14 |
2007-06-12 |
Celgene Corporation |
Pharmaceutical compositions and dosage forms of thalidomide
|
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
CN1867331B
(zh)
|
2003-09-17 |
2010-05-26 |
美国政府健康及人类服务部 |
作为TNF-α调节剂的沙利度胺类似物
|
|
US8952895B2
(en)
|
2011-06-03 |
2015-02-10 |
Apple Inc. |
Motion-based device operations
|
|
US20080027113A1
(en)
*
|
2003-09-23 |
2008-01-31 |
Zeldis Jerome B |
Methods of Using and Compositions Comprising Immunomodulatory Compounds for Treatment and Management of Macular Degeneration
|
|
US7612096B2
(en)
*
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
|
US20050100529A1
(en)
*
|
2003-11-06 |
2005-05-12 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
|
|
WO2005046593A2
(en)
*
|
2003-11-06 |
2005-05-26 |
Celgene Corporation |
Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
|
|
US20050143344A1
(en)
*
|
2003-12-30 |
2005-06-30 |
Zeldis Jerome B. |
Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
|
|
BRPI0509019A
(pt)
*
|
2004-03-22 |
2007-08-07 |
Celgene Corp |
métodos para tratar, prevenir ou controlar um distúrbio ou doença de pele, para tratar, prevenir ou controlar ceratose senil e para tratar ou controlar ceratose, composição farmacêutica, forma de dosagem unitária individual, e, kit
|
|
US20050222209A1
(en)
*
|
2004-04-01 |
2005-10-06 |
Zeldis Jerome B |
Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
|
|
EP1744749A4
(en)
*
|
2004-04-14 |
2009-04-22 |
Celgene Corp |
METHODS OF USE AND COMPOSITION COMPRISING IMMUNOMODULATOR COMPOUNDS FOR THE TREATMENT AND CARE OF MYELODYSPLASIC SYNDROMES
|
|
EP1744748A4
(en)
*
|
2004-04-14 |
2009-08-12 |
Celgene Corp |
METHOD FOR USE OF SELECTIVE CYTOKINE-INHIBITORY MEDICAMENTS AND COMPOSITIONS CONTAINING THEREOF FOR THE TREATMENT AND SUPPLY OF MYELODYSPLASTIC SYNDROMES
|
|
US20050239842A1
(en)
*
|
2004-04-23 |
2005-10-27 |
Zeldis Jerome B |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of pulmonary hypertension
|
|
ATE551060T1
(de)
*
|
2004-06-04 |
2012-04-15 |
Scripps Research Inst |
Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen
|
|
KR20070086334A
(ko)
*
|
2004-11-16 |
2007-08-27 |
리머릭 뉴로사이언스즈, 인크. |
통증을 치료하기 위한 방법 및 조성물
|
|
US20070087977A1
(en)
*
|
2004-11-16 |
2007-04-19 |
Wendye Robbins |
Methods and compositions for treating pain
|
|
JP2008520731A
(ja)
*
|
2004-11-23 |
2008-06-19 |
セルジーン・コーポレーション |
中枢神経系傷害を治療及び管理するための、免疫調節性化合物を使用した方法及び組成物
|
|
JP5710855B2
(ja)
*
|
2005-02-02 |
2015-04-30 |
ネクスジェニクス・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー |
神経線維腫の局所治療
|
|
US7442690B2
(en)
*
|
2005-03-14 |
2008-10-28 |
P & L Enterprise Llc |
Topical treatment for psoriasis
|
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
|
SMP200800012B
(it)
*
|
2005-07-22 |
2008-02-27 |
Procter & Gamble |
Composizioni per ridurre l'incidenza di aritmia indotta da farmaco
|
|
US20080138295A1
(en)
*
|
2005-09-12 |
2008-06-12 |
Celgene Coporation |
Bechet's disease using cyclopropyl-N-carboxamide
|
|
KR101430760B1
(ko)
|
2005-10-18 |
2014-08-19 |
알러간, 인코포레이티드 |
후안부 조직으로 선택적으로 침투하는 글루코코르티코이드유도체를 사용한 안과 요법
|
|
CL2007002218A1
(es)
*
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
|
EP2118075A1
(de)
|
2007-02-06 |
2009-11-18 |
Boehringer Ingelheim International GmbH |
Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
|
EP1974739A1
(en)
*
|
2007-03-21 |
2008-10-01 |
Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts |
Methods and compounds for modulating inflammatory processes
|
|
WO2009020590A1
(en)
*
|
2007-08-07 |
2009-02-12 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
|
BRPI0705396B1
(pt)
*
|
2007-12-12 |
2021-10-05 |
Universidade Estadual De Campinas - Unicamp |
Compostos derivados ftalimídicos
|
|
CA2711582A1
(en)
|
2008-02-07 |
2009-08-13 |
Boehringer Ingelheim International Gmbh |
Spirocyclic heterocycles, formulations containing said compounds, use thereof and processes for the preparation thereof
|
|
CA2733153C
(en)
|
2008-08-08 |
2016-11-08 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
|
|
BRPI0901298A2
(pt)
*
|
2009-04-06 |
2011-01-04 |
Ems Sa |
derivados ftalimìdicos de compostos antiinflamatórios não-esteróide e/ou moduladores de tnf-(alfa), processo de sua obtenção, composições farmacêuticas contendo os mesmos e seus usos no tratamento de doenças inflamatórias
|
|
US20120295979A1
(en)
*
|
2011-05-03 |
2012-11-22 |
Florida Atlantic University |
Use of sulindac for protecting retinal pigment epithelial cells against oxidative stress
|
|
US8927725B2
(en)
|
2011-12-02 |
2015-01-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Thio compounds
|
|
WO2014160702A1
(en)
|
2013-03-25 |
2014-10-02 |
Chs Pharma, Inc. |
Retinopathy treatment
|
|
US9198898B2
(en)
|
2013-06-24 |
2015-12-01 |
Tigercat Pharma, Inc. |
Use of NK-1 receptor antagonists in pruritus
|
|
US8906951B1
(en)
|
2013-06-24 |
2014-12-09 |
Tigercat Pharma, Inc. |
Use of NK-1 receptor antagonists in pruritus
|
|
AU2015210999A1
(en)
|
2014-01-29 |
2016-07-21 |
Otsuka Pharmaceutical Co., Ltd. |
Device-based risk management of a therapeutic
|
|
MA40687A
(fr)
*
|
2014-04-10 |
2017-03-28 |
Ifom Fondazione St Firc Di Oncologia Molecolare |
Méthodes et compositions de traitement de malformation vasculaire
|
|
KR20170042598A
(ko)
|
2014-08-22 |
2017-04-19 |
셀진 코포레이션 |
항체와 조합된 면역조절 화합물을 이용하여 다발성 골수종을 치료하는 방법
|
|
JP2018527302A
(ja)
|
2015-06-26 |
2018-09-20 |
セルジーン コーポレイション |
免疫調節化合物を用いたカポジ肉腫またはｋｓｈｖ誘発性リンパ腫の治療方法、及びバイオマーカーの使用
|
|
WO2017081676A1
(en)
*
|
2015-11-09 |
2017-05-18 |
Pharmatwob |
Pharmaceutical compositions and methods for treatment of cancer
|
|
US10513515B2
(en)
|
2017-08-25 |
2019-12-24 |
Biotheryx, Inc. |
Ether compounds and uses thereof
|
|
US20200254093A1
(en)
|
2017-09-14 |
2020-08-13 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatment for cancer
|
|
US10537585B2
(en)
|
2017-12-18 |
2020-01-21 |
Dexcel Pharma Technologies Ltd. |
Compositions comprising dexamethasone
|
|
AU2019309894A1
(en)
|
2018-07-27 |
2021-01-28 |
Biotheryx, Inc. |
Bifunctional compounds as CDK modulators
|
|
JP2022507267A
(ja)
|
2018-11-13 |
2022-01-18 |
バイオセリックス， インコーポレイテッド |
置換イソインドリノン
|
|
KR102143531B1
(ko)
*
|
2018-12-20 |
2020-08-12 |
영남대학교 산학협력단 |
탈리도마이드를 유효성분으로 함유하는 가축 육질 개선용 조성물
|
|
US11897930B2
(en)
|
2020-04-28 |
2024-02-13 |
Anwita Biosciences, Inc. |
Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
|